Researchers from Skyline Therapeutics (Shanghai) Co. Ltd. presented preclinical data for the new recombinant AAV vector therapeutic SKG-0106, being developed for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Pharmabcine Inc. has received IND approval from the Korean Ministry of Food and Drug Safety (MFDS) to initiate a phase I trial of PMC-403 in Korea in subjects with neovascular (wet) age-related macular degeneration (AMD).
At the recent ASGCT meeting, researchers from Exegenesis Bio Inc. presented preclinical data for EXG-102-031, a novel recombinant adeno-associated virus (rAAV)-gene therapy being developed for the treatment of neovascular age-related macular degeneration (AMD), also called wet AMD (wAMD).
MicroRNA-184 (miR-184) mutations have been previously tied to inherited anterior segment dysgenesis, potentially causing cataracts and keratoconus. To elucidate the involvement of miR-184 in ocular disorders, Chinese researchers have developed a miR-184 knockout zebrafish model. Investigators used CRISPR-Cas9 technology to delete two miR-184 paralogs (dre-mir-184-1 and dre-mir-184-2) in zebrafish, which are highly conserved between human and fly.
Azura Ophthalmics Ltd. has divulged codrugs consisting of an immunomodulator moiety and a keratolytic agent reported to be useful for the treatment of eye and dermatological disorders.
Researchers from Senelix Co. Ltd. described the preclinical characterization of the novel adiponectin receptor protein 1/2 (ADIPOR1/2) agonist SL-100, which is being developed for the treatment of dry eye disease (DED).
RSS
